Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

被引：0
|
作者：
Iosifidou, R. [1 ]
Xepapadakis, G. [2 ]
Venizelos, V. [3 ]
Markopoulos, C. [4 ]
Papazisis, K. [5 ]
Tsoulos, N. [6 ]
Kapetsis, G. [6 ]
Giannoulakis, S. [6 ]
Paraskeva, M. [7 ]
Kaparelou, M. [8 ]
Lainakis, G. [3 ]
Fotarelli, A. [1 ]
Pavlidou, F. [1 ]
Fountzilas, E. [9 ]
Saloustros, E. [10 ]
Karageorgopoulou, S. [2 ]
Triantafillidou, S. [11 ]
Intzes, S. [12 ]
Koinis, F. [10 ]
机构：
[1] Theageneio Hosp, Thessaloniki, Greece
[2] IASO Hosp, Athens, Greece
[3] Metropolitan Hosp, Athens, Greece
[4] Athens Med Ctr, Maroussi, Greece
[5] EuroMed Clin, Thessaloniki, Greece
[6] Genekor SA, Athens, Greece
[7] Gen Hosp Rodos, Rodos, Greece
[8] Alexandra Gen Hosp, Athens, Greece
[9] St Lukes Hosp, Thessaloniki, Greece
[10] Univ Hosp Larisa, Larisa, Greece
[11] Genesis Hosp, Athens, Greece
[12] Interbalcan European Med Ctr, Thessaloniki, Greece
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P050
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of the Oncotype DX® Recurrence Score® Assay on therapy recommendations for ER-positive (ER+), node negative (N0) and node positive (N+) early breast cancer - Results of an interim analysis of the German decision impact study
    Blohmer, J. -U.
    Rezai, M.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I
    Eidtmann, H.
    Kaufmann, M.
    Eiermann, W.
    ONKOLOGIE, 2011, 34 : 119 - 120
  • [22] Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer
    McAuliffe, Priscilla F.
    Carleton, Neil M.
    Zou, Jian
    Fang, Yusi
    Koscumb, Stephen E.
    Shah, Osama
    Chen, Fangyuan
    Beriwal, Sushil
    Diego, Emilia J.
    Brufsky, Adam M.
    Oesterreich, Steffi
    Shapiro, Steve D.
    Ferris, Robert
    Emens, Leisha A.
    Tseng, George
    Marroquin, Oscar C.
    Lee, Adrian V.
    CANCER RESEARCH, 2021, 81 (04)
  • [23] News on the medical treatment of young women with early-stage HER2-negative breast cancer
    Lambertini, Matteo
    Poggio, Francesca
    Vaglica, Marina
    Blondeaux, Eva
    Del Mastro, Lucia
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1643 - 1655
  • [24] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Su Hyun Lee
    Seunggyun Ha
    Hyun Joon An
    Jae Sung Lee
    Wonshik Han
    Seock-Ah Im
    Han Suk Ryu
    Won Hwa Kim
    Jung Min Chang
    Nariya Cho
    Woo Kyung Moon
    Gi Jeong Cheon
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1574 - 1584
  • [25] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Lee, Su Hyun
    Ha, Seunggyun
    An, Hyun Joon
    Lee, Jae Sung
    Han, Wonshik
    Im, Seock-Ah
    Ryu, Han Suk
    Kim, Won Hwa
    Chang, Jung Min
    Cho, Nariya
    Moon, Woo Kyung
    Cheon, Gi Jeong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1574 - 1584
  • [26] A novel scoring system based on the clinical and genomic variables to predict the early relapse in estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer
    Lin, Caijin
    Wu, Jiayi
    Ding, Shuning
    Andriani, Lisa
    Chen, Weilin
    Liu, Deyue
    Zhu, Li
    CANCER RESEARCH, 2020, 80 (04)
  • [27] CD45-positive tumor infiltrating lymphocytes in early-stage hormone-positive, HER2negative (ER+/HER2-) breast cancer: Correlation with proliferation and prognostic signature scores.
    Lucas, Mairi
    Kinsella, Zak
    Gonzalez, Claudia Aura
    Hurley, Camille
    Blumel, Anna
    Fay, Joanna
    O'Grady, Anthony
    Murphy, Verena
    Jahangir, Chowdhury Arif
    Burke, Caoimbhe
    Rahman, Arman
    Crown, John
    Kelly, Catherine Margaret
    Gallagher, William M.
    O'Connor, Darran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2-Node-Negative Breast Cancer in the Netherlands
    de Jongh, Felix E.
    Efe, Reva
    Herrmann, Kirsten H.
    Spoorendonk, Jelle A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2022, 2022
  • [29] The comprehensive genomic profiling in early-stage (T1-2N0-1M0) breast cancer
    Chen, Bo
    Li, Yingzi
    Zhang, Yuchen
    Zhang, Guochun
    Du, Haiwei
    Sun, Dailin
    Li, Junjun
    Liao, Ning
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2-breast cancer with low or intermediate tumor proliferation
    Sinn, Peter
    Kriegsmann, Mark
    Felten, Ute
    Wacker, Juergen
    Schneeweiss, Andreas
    Varga, Zsuzsanna
    CANCER RESEARCH, 2015, 75
12345